Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor, for the treatment of Acute Myeloid Leukemia (AML). Under the…

A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes validates Yatiri Bio’s platform as a breakthrough in oncology patient stratification.  Yatiri Bio, a precision medicine company utilizing an AI-driven proteomic platform (ProteoCharts™) to identify therapeutically…

Yatiri Bio Inc. today announced it has received a grant from the Gates Foundation to launch a one-year project, Proteomics Interoperability, aimed at improving how large-scale proteomics data can be integrated and applied to global health challenges.  Proteomics, the large-scale study of proteins,…

Yatiri Bio, Inc., a leader in proteomics-driven precision medicine, today announced the successful acquisition of NGeneBioAI, Inc., a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition strengthens Yatiri Bio’s position at the forefront of biomarker…

Yatiri Bio Inc. is pleased to announce that Professor Jennifer Van Eyk has joined Yatiri Bio as an advisory board member.  Professor Van Eyk is a renowned international scientist in the field of clinical proteomics and serves as the Erika…

Yatiri Bio Inc. today announced the addition of Dr. Carl Goldfischer to Yatiri Bio’s strategic advisory board.   Dr. Carl Goldfischer has 30 years of investment, and his background includes extensive public and private investment and transaction work, as well…

Yatiri Bio Inc. today announced the addition of Michael J. Kamdar, former CEO and President of Molecular Assemblies to the company’s strategic advisory board. “We are honored and grateful to have Mike join our Advisory Board,” said CEO Pilgrim…

Yatiri Bio attended the 65th annual American Society for Hematology meeting in San Diego, CA from December 9 – 12. Yatiri Bio was fortunate to be selected for a poster presentation that highlights the further development of our technology for…

Yatiri Bio and Fred Hutch Cancer Center (FHCC) have entered into a Research Collaboration Agreement that focuses on using AML patient proteomic data from the Stirewalt lab processed through Yatiri Bio’s bioinformatic pipeline with the goals of: A publication…

Yatiri Bio Inc. was selected by Connect as a 2023 Cool Company (https://connect.org/class-of-2023-cool-companies/).  Out of 300 companies, we were selected as one of 39 rising startups in the San Diego area.  This announcement reaffirms our vision that utilizing proteomics and machine learning…

Yatiri Bio and Ordaōs Announce a Joint Development Agreement to Create Novel Therapeutics for AML  The Partnership will Interrogate Patient Proteome Data to Drive Drug Discovery for high-risk subsets of Acute Myeloid Leukemia (AML) SAN DIEGO, CA, December 15,…

   Yatiri Bio Inc. is pleased to announce a collaboration agreement in Ovarian Cancer (OC) with South Coast Gynecologic Oncology, Inc. (SCGOI).  This work will center around the discovery of novel predictive biomarkers and new targets using global proteomics data…

Yatiri Bio Inc. is pleased to announce that Professor Jill Mesirov has joined Yatiri Bio as an advisory board member.  Professor Mesirov is a senior institute fellow of the Broad Institute, and associate vice chancellor for computational health sciences and…